In vivo binding of [68Ga]-DOTATOC to somatostatin receptors in neuroendocrine tumours--impact of peptide mass.
about
68Ga-Based radiopharmaceuticals: production and application relationshipRecent developments in imaging of pancreatic neuroendocrine tumorsCurrent knowledge on the sensitivity of the (68)Ga-somatostatin receptor positron emission tomography and the SUVmax reference range for management of pancreatic neuroendocrine tumoursNovel Method for Radiolabeling and Dimerizing Thiolated Peptides Using (18)F-HexafluorobenzeneEGFR-expression in primary urinary bladder cancer and corresponding metastases and the relation to HER2-expression. On the possibility to target these receptors with radionuclides.Therapeutic application of CCK2R-targeting PP-F11: influence of particle range, activity and peptide amountReduction of (68)Ge activity containing liquid waste from (68)Ga PET chemistry in nuclear medicine and radiopharmacy by solidificationHow Does the Patient Benefit from Clinical PET?EANM 2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma.Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [68Ga]ABY-025 Affibody PET/CT.Does PRRT with standard activities of 177Lu-octreotate really achieve relevant somatostatin receptor saturation in target tumor lesions?: insights from intra-therapeutic receptor imaging in patients with metastatic gastroenteropancreatic neuroendocrProspective of ⁶⁸Ga-radiopharmaceutical development.Repeatability of gallium-68 DOTATOC positron emission tomographic imaging in neuroendocrine tumors.Neuroendocrine tumours: the role of imaging for diagnosis and therapy.Gastrointestinal neuroendocrine tumors (NETs): new diagnostic and therapeutic challenges.Nordic guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms.Continued rapid growth in (68) Ga applications: update 2013 to June 2014.Dual-Nuclide Radiopharmaceuticals for Positron Emission Tomography Based Dosimetry in Radiotherapy.Current advances in ligand design for inorganic positron emission tomography tracers (68)Ga, (64)Cu, (89)Zr and (44)Sc.68Ga-DOTA and analogs: Current status and future perspectivesTime-integrated activity coefficient estimation for radionuclide therapy using PET and a pharmacokinetic model: A simulation study on the effect of sampling schedule and noise.Comparative gallium-68 labeling of TRAP-, NOTA-, and DOTA-peptides: practical consequences for the future of gallium-68-PET.Optimal specific radioactivity of anti-HER2 Affibody molecules enables discrimination between xenografts with high and low HER2 expression levels.Fully automated GMP production of [68Ga]Ga-DO3A-VS-Cys40-Exendin-4 for clinical use.Good manufacturing practice production of [(68)Ga]Ga-ABY-025 for HER2 specific breast cancer imaging.The amount of injected 177Lu-octreotate strongly influences biodistribution and dosimetry in C57BL/6N mice.Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F-DOPA.Changes in biodistribution on 68Ga-DOTA-Octreotate PET/CT after long acting somatostatin analogue therapy in neuroendocrine tumour patients may result in pseudoprogression.68Ga-DOTA-TOC uptake in neuroendocrine tumour and healthy tissue: differentiation of physiological uptake and pathological processes in PET/CT.Comparison of sequential planar 177Lu-DOTA-TATE dosimetry scans with 68Ga-DOTA-TATE PET/CT images in patients with metastasized neuroendocrine tumours undergoing peptide receptor radionuclide therapy.A methodical 68Ga-labelling study of DO2A-(butyl-L-tyrosine)2 with cation-exchanger post-processed 68Ga: practical aspects of radiolabelling.Prospective of 68Ga Radionuclide Contribution to the Development of Imaging Agents for Infection and Inflammation.Preparation and evaluation of a 68Ga-labeled RGD-containing octapeptide for noninvasive imaging of angiogenesis: biodistribution in non-human primate.MEDICINAL RADIOPHARMACEUTICAL CHEMISTRY OF METAL RADIOPHARMACEUTICALS
P2860
Q26801794-0FDCDEBD-6A11-4056-9905-134017D2658CQ27005697-3C16F4CE-8909-4DA6-92DC-6507DF3E4C83Q28071483-FB8B08B5-37B8-4E82-B612-D2E74E031A16Q28817842-36790DED-4587-484E-8429-2C8C0ED6B37AQ35184816-3CF703AA-60F3-4E50-A5B4-8AA7B5CDD888Q35675498-2397B6B6-F386-4B70-B607-8D06CD8CBF75Q35888298-6A3137FB-9932-425F-8745-D21B7F0BEFBCQ35988082-3D0365E7-7D72-4C6A-BDBE-6E0B9997A468Q36467722-981800E5-8986-44AB-8D2F-7273C8622049Q36510875-8BB66535-632D-400B-85DF-A91BF81DDF83Q37425156-7B5E7589-BA09-4312-9207-75158BB2DE33Q37435222-F41F26C6-CC91-4B05-96C4-CCF2B38A927DQ37504159-3435469B-F26F-4BE2-98BB-E07BF86D53E0Q38169928-A3973BEF-8FCB-497C-860E-52BCC56DB9ADQ38175857-F1D6E1FE-3C13-41D8-BBDA-8D1F2822FF0BQ38241601-00996BFE-039A-4B85-9A8B-C5FE4BD59548Q38358666-8977DFF2-3770-4EED-AF09-E1FA3A859C29Q38612027-624F05FE-F6A6-45DB-B898-0947B1474C7FQ38729041-8B112D1A-8D0B-41A4-82E9-BFE93C2309E2Q39191325-DD987449-5051-4D55-82CC-A00BE703B21CQ39430065-955799BB-6C70-4C39-A016-A5D358518F40Q39605627-2E7DB2B6-71A4-4178-8308-6770461C4CF7Q39633289-6525E5B1-8DDE-42D5-9712-FA1ABBEEED6DQ41019277-DD5A7D3B-8B74-43EC-AF1D-E0881A7C92C6Q41083360-F8A198D5-E444-4635-82D9-0BE99CD0A575Q47730141-1550CAB7-7F60-48D6-B43B-71600DBBF17FQ48089118-490492E0-E043-4D10-AB0B-59526CF8896CQ49451226-E37BE107-23BD-4145-BEB9-659880D45048Q53125755-44C32903-A72F-488A-8CAC-2C34718D4988Q53184931-041B4FAC-C5BF-49A4-88B3-499D0A7C5413Q53187330-C1B9390E-FE5D-4C14-88D1-6ECB45AFF93EQ54257268-B8D00E9D-BD92-4F0F-8B2C-282E54A18980Q55098453-4D9C129A-DB9C-45AE-9458-83587A39EBE9Q56619661-4087AD24-46F1-407E-87B1-6B1B76610735
P2860
In vivo binding of [68Ga]-DOTATOC to somatostatin receptors in neuroendocrine tumours--impact of peptide mass.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
In vivo binding of [68Ga]-DOTA ...... mours--impact of peptide mass.
@ast
In vivo binding of [68Ga]-DOTA ...... mours--impact of peptide mass.
@en
In vivo binding of [68Ga]-DOTA ...... mours--impact of peptide mass.
@nl
type
label
In vivo binding of [68Ga]-DOTA ...... mours--impact of peptide mass.
@ast
In vivo binding of [68Ga]-DOTA ...... mours--impact of peptide mass.
@en
In vivo binding of [68Ga]-DOTA ...... mours--impact of peptide mass.
@nl
prefLabel
In vivo binding of [68Ga]-DOTA ...... mours--impact of peptide mass.
@ast
In vivo binding of [68Ga]-DOTA ...... mours--impact of peptide mass.
@en
In vivo binding of [68Ga]-DOTA ...... mours--impact of peptide mass.
@nl
P2093
P1476
In vivo binding of [68Ga]-DOTA ...... mours--impact of peptide mass.
@en
P2093
Anders Sundin
Barbro Eriksson
Hans Lundqvist
Irina Velikyan
Jens Sörensen
Mats Bergström
P304
P356
10.1016/J.NUCMEDBIO.2009.11.008
P577
2010-01-15T00:00:00Z